Порівняння методів
Переглядайте обрані методи поруч; рядки з відмінностями підсвічено.
| Опитувальник щодо хвороби Паркінсона-39× | EORTC QLQ-C30× | |
|---|---|---|
| Галузь | Наслідки для здоров'я | Наслідки для здоров'я |
| Родина | Process / pipeline | Process / pipeline |
| Рік появи≠ | 1997 | 1993 |
| Автор методу≠ | Crispin Jenkinson et al. | Nico Aaronson et al. |
| Тип | Self-report quality of life questionnaire | Self-report quality of life questionnaire |
| Основоположне джерело≠ | Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age and Ageing, 26(5), 353-357. DOI ↗ | Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. DOI ↗ |
| Інші назви | PDQ-39, Parkinson's Disease Questionnaire, PDQ | QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale |
| Пов'язані≠ | 4 | 5 |
| Підсумок≠ | The PDQ-39 is the most widely used patient-reported outcome measure for Parkinson's disease quality of life. Developed by Crispin Jenkinson and colleagues in 1997, this 39-item self-report questionnaire comprehensively assesses how Parkinson's symptoms affect daily functioning, emotional well-being, stigma, social support, and cognitive-communication abilities. It is the recommended instrument in major Parkinson's disease clinical trials and forms a core component of outcome measurement in movement disorders. | The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care. |
| ScholarGateНабір даних ↗ |
|
|